Targeting the cancer initiating cell: the ultimate target for cancer therapy.

MLA

McCubrey, James A., et al. “Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy.” Current Pharmaceutical Design, vol. 18, no. 13, 2012, pp. 1784–95. EBSCOhost, https://doi.org/10.2174/138161212799859701.

APA

McCubrey, J. A., Steelman, L. S., Abrams, S. L., Misaghian, N., Chappell, W. H., Basecke, J., Nicoletti, F., Libra, M., Ligresti, G., Stivala, F., Maksimovic-Ivanic, D., Mijatovic, S., Montalto, G., Cervello, M., Laidler, P., Bonati, A., Evangelisti, C., Cocco, L., & Martelli, A. M. (2012). Targeting the cancer initiating cell: the ultimate target for cancer therapy. Current Pharmaceutical Design, 18(13), 1784–1795. https://doi.org/10.2174/138161212799859701

Chicago

McCubrey, James A, Linda S Steelman, Stephen L Abrams, Negin Misaghian, William H Chappell, Jorg Basecke, Ferdinando Nicoletti, et al. 2012. “Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy.” Current Pharmaceutical Design 18 (13): 1784–95. doi:10.2174/138161212799859701.